Is Tvardi Therapeutics, Inc. (TVRD) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2023
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.0% / 30% | 62.2% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 1.0% / 33% | 62.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 1.4% / 33% | 84.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 1.0% / 33% | 62.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 1.4% / 33% | 84.9% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -135.6% | |
| Return on Assets (ROA) | -72.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$21M |
| Free Cash Flow | -$21M |
| Total Debt | $368,000 |
| Debt-to-Equity | 0.8 |
| Current Ratio | 3.5 |
| Total Assets | $27M |
Price & Trading
| Last Close | $3.33 |
| 50-Day MA | $3.88 |
| 200-Day MA | $14.80 |
| Avg Volume | 80K |
|
52-Week Range
$3.15
| |
About Tvardi Therapeutics, Inc. (TVRD)
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Tvardi Therapeutics, Inc. (TVRD) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Tvardi Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Tvardi Therapeutics, Inc.'s debt ratio?
Tvardi Therapeutics, Inc.'s debt ratio is 1.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.4%.
What are Tvardi Therapeutics, Inc.'s key financial metrics?
Tvardi Therapeutics, Inc. has a market capitalization of $30M. Return on equity stands at -135.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.